Grant Title: EPIDEMIOLOGY OF DRUG ABUSE (R03, R21)

PA Number: PA-06-329; PA-06-330

Area of Research: Early and conceptual research development to advance scientific knowledge about the epidemiology of drug abuse.

Release and Expiration: April 7, 2006 release; September 2, 2007 expiration.

Annual Deadline: R03, R21-New: February 16, June 16, October 16 annually; Resubmissions: March 16, July 16, November 16 annually; AIDS Related: May 1, September 1, January 2 annually.

Amount: R03: $50,000 per year; maximum of $100,000 over a 2 year period; R21: $275,000 direct costs for the 2 year period

Length of Support: R03: 2 years; R21: 2 years

Eligible Applicants: For profit organizations; Non-profit organizations; Public or private institutions, such as universities, colleges, hospitals and laboratories; Units of State government; Units of local government; Eligible agencies of the Federal government; Domestic institutions; Foreign institutions; Faith-based or community-based organizations; Units of State Tribal government; and Units of Local Tribal government.

Agency/ Department: NIH; NIDA

Summary: The purpose of this funding opportunity is to support exploratory/ developmental research projects that address 1) drug use patterns and trends within and across populations; (2) interplay of social interactions, social environment, structural context with individual behavioral characteristics and genetic vulnerability; (3) the phenotypic heterogeneity of drug abuse; (4) causal mechanisms leading to onset, maintenance, and remittance of drug abuse, as well as protective mechanisms that reduce the risk of drug abuse; and (5) drug abuse over the life course, including developmental processes that influence drug use trajectories and behavioral, health, and social consequences of drug abuse. In addition, research is encouraged to develop methodologies to improve the accuracy, efficiency, scope, timeliness, and analytic yield of drug abuse epidemiologic data. Major programs areas include: emerging and current trends; social epidemiology of drug abuse; familial/genetic liability and phenotypic heterogeneity; drug abuse psychopathology: co-morbidity and vulnerability; human development in adolescence and adulthood; developmental consequences of drug abuse; social and behavioral consequences of street drugs; and drug markets and behavior economics.